HomeCompareHXBM vs MRK

HXBM vs MRK: Dividend Comparison 2026

HXBM yields 200.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HXBM wins by $119.31M in total portfolio value
10 years
HXBM
HXBM
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full HXBM calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — HXBM vs MRK

📍 HXBM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHXBMMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HXBM + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HXBM pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HXBM
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, HXBM beats the other by $51,141,353.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HXBM + MRK for your $10,000?

HXBM: 50%MRK: 50%
100% MRK50/50100% HXBM
Portfolio after 10yr
$59.71M
Annual income
$30,092,947.21/yr
Blended yield
50.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

HXBM
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HXBM buys
0
MRK buys
0
No recent congressional trades found for HXBM or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHXBMMRK
Forward yield200.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$119.36M$56.8K
Annual income after 10y$60,176,096.29$9,798.13
Total dividends collected$112.49M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HXBM vs MRK ($10,000, DRIP)

YearHXBM PortfolioHXBM Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$30,700$20,000.00$11,206$366.19+$19.5KHXBM
2$90,232$57,383.18$12,650$502.35+$77.6KHXBM
3$254,173$157,624.56$14,407$694.19+$239.8KHXBM
4$686,927$414,961.74$16,585$967.82+$670.3KHXBM
5$1,783,118$1,048,106.39$19,342$1,363.89+$1.76MHXBM
6$4,450,613$2,542,677.12$22,913$1,947.19+$4.43MHXBM
7$10,693,420$5,931,263.38$27,662$2,823.89+$10.67MHXBM
8$24,760,608$13,318,648.86$34,159$4,173.35+$24.73MHXBM
9$55,315,649$28,821,798.66$43,337$6,308.80+$55.27MHXBM
10$119,363,841$60,176,096.29$56,776$9,798.13+$119.31MHXBM

HXBM vs MRK: Complete Analysis 2026

HXBMStock

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.

Full HXBM Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this HXBM vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HXBM vs SCHDHXBM vs JEPIHXBM vs OHXBM vs KOHXBM vs MAINHXBM vs JNJHXBM vs ABBVHXBM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.